Pediatrix Medical Group (NYSE:MD) reported fourth-quarter results that matched its recently raised internal projections, as the company’s multi-year restructuring begins to yield a more predictable, hospital-centric financial profile.
For the quarter ended December 31, 2025, Pediatrix posted net revenue of $494 million, a slight decrease from the $502.4 million reported in the prior-year period.
This decline was primarily attributed to the planned divestiture of office-based practices.
However, same-unit net revenue grew by 4%, driven by improved collections and higher patient acuity in its core neonatology and hospital-based practices.
On the bottom line, the company reported net income of $34 million, or $0.40 per share.
On an adjusted basis, EPS stood at $0.50, narrowly missing analyst estimates of $0.54 as the company absorbed higher variable practice incentive compensation.
Adjusted EBITDA for the quarter was $66 million.
Looking toward 2026, the company expects to see continued benefit from its hybrid revenue cycle management model.
While patient service volumes saw a modest 2.7% dip in the quarter, the shift toward a more favorable payor mix and increased administrative fees from hospital partners provided a robust cushion.